Revive Therapeutics Announces Proposed Shares for Debt Transaction

TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announces that it is proposing to settle an aggregate of $150,000 in payables to arm’s length parties through the issuance of up to 6,000,000 common shares, at a proposed issue price of $0.025 per share (the “Shares for Debt Transaction”). The issue price is based upon the 20-day VWAP of the shares traded on the CSE.